879-56-1

Basic information

• Product Name: 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE
• Synonyms: 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE;1,2,3,4-Tetrahydro-7-methoxyquinolone
• CAS NO: 879-56-1
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• EINECS: 604-604-1
• Mol File: 879-56-1.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE(879-56-1)
• EPA Substance Registry System: 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE(879-56-1)

Safety Data

• Hazardous Substances Data: 879-56-1(Hazardous Substances Data)

Usage

General Description

7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE is a chemical compound with the molecular formula C10H11NO2. It is a derivative of quinolinone and is often used in medicinal and pharmaceutical research. 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE has been studied for its potential pharmacological activities, including its use as an anticonvulsant and as a potential treatment for neurodegenerative diseases. Additionally, 7-METHOXY-2,3-DIHYDROQUINOLIN-4(1H)-ONE has demonstrated potential as an inhibitor of enzymes, making it a target for drug development. Research in this area continues to explore the potential therapeutic applications of this chemical compound.

Upstream product

• 61999-50-6 N-(3-methoxyphenyl)azetidin-2-one 
• 1216002-27-5 3-bromo-N-(3-methoxyphenyl)propanamide 
• 766-85-8 3-methoxy-1-iodobenzene 
• 15908-77-7 N-benzenesulfonyl-N-(3-methoxy-phenyl)-β-alanine 
• 75227-24-6 ethyl 3-(3-methoxyphenylamino)propionate 
• 536-90-3 m-Anisidine 
• 42313-49-5 methyl 3-(3-methoxyanilino)propionate 
• 3334-67-6 3-((3-methoxyphenyl)amino)propanoic acid 
• 21988-35-2 1-Benzolsulfonyl-4-oxo-7-methoxy-1,2,3,4-tetrahydro-chinolin 

Downstream Products

• 53518-16-4 4-trifluoromethyl-6,7,8,9-tetrahydro-pyrano[3,2-g]quinolin-2-one 
• 58196-33-1 7-hydroxy-1,2,3,4-tetrahydroquinoline 
• 190516-85-9 7-methoxy-4(1H)-oxoquinoline 
• 1374229-60-3 C₂₂H₂₁FN₂O₄S 
• 1374232-98-0 C₂₁H₁₈FNO₅S 
• 1374232-96-8 C₂₀H₁₈FNO₃S 
• 1374232-97-9 C₂₂H₂₀FNO₅S 
• 1374232-95-7 C₂₆H₃₂FNO₄SSi 
• 179897-99-5 1-tert-butoxycarbonyl-1,2,3,4-tetrahydro-7-methyloxy-4-quinolinone 
• 907998-92-9 5-benzyl-7-methoxy-1-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline 
• 907998-91-8 5-benzyl-7-methoxy-1-phenyl-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline 
• 907999-29-5 7-methoxy-1-(4-methoxyphenyl)-3-phenyl-1H-pyrazolo[4,3-c]quinoline 
• 907999-28-4 7-methoxy-1,3-diphenyl-1H-pyrazolo[4,3-c]quinoline 

Relevant articles and documents

HETEROCYCLIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF

The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and /or diagnostics.

INHIBITORS OF HEPATITIS C VIRUS

A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.

COMPOUND

There is provided a compound having Formula (I) wherein each of R1, R2, R4, R5, R6 and R7 are independently selected from (a) H, (b) R17, -OC(R17)3, -OCH(R17)2, -(OCH2R)17, -C(R17)3, -CH(R17)2, or -CH2R17 wherein R17 is a halogen; (c) -CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) -SO2-alkyl; and (n) -N(R11)C(O)R13; wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl ; each of rings A and B are selected from five or six membered carbon rings optionally containing one or more hetero atoms selected from N, S, and O and optionally having fused thereto a further ring; X is an optional group selected from O, S, S=O, S(=O)2, C=O, S(=O)2NR8, C=ONR9, NR10, wherein R8, R9 and R10 are independently selected from H and hydrocarbyl, wherein n and p are independently selected from O and 1 ; Y is (R11)1-3 wherein each R11 is independently selected from NR12, CR13R14, S(=O)2 and C=O, wherein R12, R13 and R14 are independently selected from H and hydrocarbyl; Z is selected from (i) six or seven membered ring containing carbon and at least one nitrogen, which may be optionally substituted wherein the substituents may together form further ring fused thereto; and (ii) a -R15-NR16- group wherein R15 is an optionally substituted C1-6 alkyl chain and R16 is selected from H and hydrocarbyl; and R3 is selected from Formula (A).